Factor Model (net +0.3)
Factor Model
net +0.3 1.2 / 10Canaccord Cuts OFIX Target 17% Despite Keeping Buy
Watch: Track H2 2026 VIRATA launch and early adoption trends. Execution on product launches and delivery of the guided $95–98M EBITDA range will determine if Canaccord's Buy persists or faces further cuts.
Canaccord reduced its OFIX price target from $24 to $20 following Q4 2025 results and updated 2026 guidance, but held its Buy rating. The company is projecting adjusted EBITDA of $95–98 million and positive free cash flow for 2026, with VIRATA scheduled for full H2 2026 launch and TRUELOK Elevate and FITBONE expected to contribute full-year revenue.
A 17% target cut signals analyst concern about near-term valuation or execution risk, even with maintained conviction. The survival of the Buy rating suggests confidence in 2026 drivers, but the valuation reset indicates the market may need to prove those products can deliver as promised.
Evidence
6 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when OFIX changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.